Poolbeg Pharma PLC
Research Poolbeg Pharma PLC (POLB) on Bullrun: market cap GBX 6.57B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPOLB
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 6.57B
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 5.70M
- Free cash flow-GBP 4.84M
Valuation Snapshot
latest market cap is GBX 6.57B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 5.70M | -GBP 4.84M | n/a | -0.01 | GBP 7.71M | n/a | GBP 8.60M |
| FY2024 | GBP 0 | -GBP 5.79M | -GBP 4.78M | n/a | -0.01 | GBP 7.82M | n/a | GBP 9.27M |
| FY2023 | GBP 0 | -GBP 3.93M | -GBP 4.56M | n/a | -0.01 | GBP 12.17M | n/a | GBP 14.44M |
| FY2022 | GBP 0 | -GBP 4.69M | -GBP 4.97M | n/a | -0.01 | GBP 16.19M | n/a | GBP 18.32M |
| FY2021 | GBP 0 | -GBP 2.34M | -GBP 2.23M | n/a | -0.01 | GBP 20.95M | n/a | GBP 22.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | GBX 6.57B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Poolbeg Pharma PLC's market cap?
Poolbeg Pharma PLC's market capitalization is GBX 6.57B.
What does Poolbeg Pharma PLC do?
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.